A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

2007405 citationsJournal Article

Authors

Eric J. Small · University of California, San Francisco

N. Simon Tchekmedyian · Cardiovascular Medical Group

Brian I. Rini · Cleveland Clinic

Lawrence Fong · University of California, San Francisco

Israel Lowy

James P. Allison · Memorial Sloan Kettering Cancer Center

Abstract

A single dose of 3 mg/kg Ipilimumab, an anti-CTLA-4 antibody, given to patients with prostate cancer is safe and does not result in significant clinical autoimmunity. PSA-modulating effects observed warrant further investigation.

Topics & Keywords

Cancer Immunotherapy and Biomarkers T-cell and B-cell Immunology Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 13, Issue 6, pp. 1810-1815

DOI: 10.1158/1078-0432.ccr-06-2318

Field-Weighted Citation Impact: 15.01